Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus ZYRTEC.
PHENERGAN VC vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine